menu
    • menu

    Company profile for OcuTerra Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity. OcuTerra a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current st...
    OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity. OcuTerra a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch and wait” does not prevent or control the progression of disease

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OcuTerra TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    50 Milk Street 16th Floor Boston MA 02109
    Telephone
    Telephone
    (617) 701-7382
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ocuterratx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ocuterra-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Phase 2 fail sends OcuTerra's eye drop dreams down the drain
    Phase 2 fail sends OcuTerra's eye drop dreams down the drain

    14 Mar 2024

    // Gabrielle Masson FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/ph-2-fail-sends-ocuterras-eye-drop-dreams-down-drain

    Gabrielle Masson FIERCE BIOTECH
    14 Mar 2024
    Share Share
    OcuTerra to Present at 42nd Annual J.P. Morgan Healthcare Conference
    OcuTerra to Present at 42nd Annual J.P. Morgan Healthcare Conference

    04 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240104045633/en

    BUSINESSWIRE
    04 Jan 2024
    Share Share
    OcuTerra Announces Last Patient Completes Final Visit in Nesvategrast
    OcuTerra Announces Last Patient Completes Final Visit in Nesvategrast

    03 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240103754817/en

    BUSINESSWIRE
    03 Jan 2024
    Share Share
    OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of OTT166
    OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of OTT166

    18 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230718647783/en

    BUSINESSWIRE
    18 Jul 2023
    Share Share
    OcuTerra Appoints Bill Steinkrauss as Chief Financial Officer
    OcuTerra Appoints Bill Steinkrauss as Chief Financial Officer

    01 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230601005385/en

    BUSINESSWIRE
    01 Jun 2023
    Share Share
    OcuTerra Reports Publication of OTT166 Biological Activity Data from Ph1b Study
    OcuTerra Reports Publication of OTT166 Biological Activity Data from Ph1b Study

    19 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221019005275/en

    BUSINESSWIRE
    19 Oct 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search